Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CARDIOREPAIR

Financiado

Cerrado

Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics App...

Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions In CARDIOREPAIR, we aim to identify and repair disease-causing variants in dilated cardiomyopathy (DCM), the major contributor to heart failure. We focus on the gene RBM20 mutated in patients with a highly penetrant and aggressive... ver más

30/09/2028

EMBL

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

EUROPEAN MOLECULAR BIOLOGY LABORATORY No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-26

HORIZON-EIC-2022-PATHFINDERCHALLENGES-01-03: EIC Pathfinder Challenge: Cardiogen... Scope:Cardiogenomics holds the potential to address existing gaps in the diagnosis and treatment of...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

EMBL

2.18M€ | Lider

HMGU

2.17M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TITINmap Towards Uncovering the Splicing Code of the Gigantic Gene Ti... 176K€ Cerrado

BIO2011-25369 BUSQUEDA RAPIDA Y RENTABLE DE CARDIOMIOPATIAS MEDIANTE ANALI... 145K€ Cerrado

SAF2009-08367 MIOCARDIOPATIA DIABETICA; MECANISMOS MOLECULARES Y BIOMARCAD... 121K€ Cerrado

DCM-NEXT Enabling advances in diagnosis, patient stratification and t... 4M€ Cerrado

INDIVUHEART Individualized early risk assessment for heart diseases 2M€ Cerrado

BFU2016-75144-R ANALISIS MOLECULAR DEL EFECTO DEL EJERCICIO EN EL DESARROLLO... 194K€ Cerrado

Duración del proyecto: 63 meses Fecha Inicio: 2023-06-26
Fecha Fin: 2028-09-30

Líder del proyecto

EUROPEAN MOLECULAR BIOLOGY LABORATORY No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In CARDIOREPAIR, we aim to identify and repair disease-causing variants in dilated cardiomyopathy (DCM), the major contributor to heart failure. We focus on the gene RBM20 mutated in patients with a highly penetrant and aggressive form of familial DCM. We will create a comprehensive map of all possible RBM20 variants that can cause DCM and develop a therapeutic approach for mutations with the strongest effect size. Enabled by a multitude of new technologies developed in our groups, the primary goal is to characterize the complete spectrum of amino acid mutations in RBM20 by high-throughput saturation mutagenesis screens. Combined with functional readouts and multi-omics analysis of downstream processes, we will classify and score the pathogenicity of each individual mutant (objective 1). To this end, we will cover both the known DCM-causing RBM20 variants, as well as those that have not been identified in patients yet. Each mutant, represented by a typical transcriptomic, proteomic, phosphoproteomic, and microscopic fingerprint, will guide us in finding novel class-specific therapeutic strategies to revert the deviant phenotype back to the healthy state. For a subset of mutants representing each identified mutation class, we will generate mouse models and investigate changes in heart physiology and ultrastructure linked to the altered ‘ome’ profile. Our second goal is to establish a class-specific therapeutic approach for the treatment of patients harboring RBM20 mutations (objective 2). We will implement our advances in muscle-specific gene editing, focusing on prime editing and nanobody-guided approaches to specifically tackle the mutations leading to RBM20 translocation. This proposal serves as a blueprint for going from variant identification to therapy in an accelerated fashion by harnessing and combining the power of high-throughput functional genomics and bioengineering and therefore is widely applicable to other cardiovascular diseases (CVD).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores